中国药厂成功“仿制”瑞德西韦目前正在量产中光华日报

12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Thu, 03 Apr 2025 20:39:11 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Vary: Accept-Encoding [5] => X-Powered-By: PHP/7.4.33 [6] => Cache-Control: no-cache, private [7] => Set-Cookie: UpalLiveSession=eyJpdiI6IkdpNmZJMHloUFlvelRjNTdcLzVpKzhRPT0iLCJ2YWx1ZSI6InBVNUJhXC9YZG43emo4Y1wvQXAyd3RibzNGeCtrc2Z4ekhKV1lpYzJ0eVJHcW5Ld3dkTVwvOHJmZkdNVjMwWjlSRjYzRjBBaDhvaUZkRjdSNHNNVXZIYXJRPT0iLCJtYWMiOiIwMTRmNGNjZTY1ODZhODhjYWVlMDhhODc5ZjhiZGMxMjMwOWVjYTE5ODUxNDQxMTQyYmRiNmVhMzc0ZGVhMzBiIn0%3D; expires=Sun, 02-Apr-2028 13:50:34 GMT; Max-Age=94608000; path=/; HttpOnly [8] => X-Frame-Options: SAMEORIGIN [9] => X-XSS-Protection: 1; mode=block [10] => X-Content-Type-Options: nosniff [11] => Referrer-Policy: no-referrer-when-downgrade [12] => cf-cache-status: DYNAMIC [13] => Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=ggFMNoQH%2FoESabXkUDIwKG4qTcuBuxoB1e3bEyTdjMjjaMAhi3mRxv%2B2%2BHKc3S4%2B5%2FMl%2FpiUFn0rC1uSMC0YUld3C9kqIdZqSKWu6p7fmwUDcBWisrhoUwQSP81fTWNC6Mw%3D"}],"group":"cf-nel","max_age":604800} [14] => NEL: {"success_fraction":0,"report_to":"cf-nel","max_age":604800} [15] => Server: cloudflare [16] => CF-RAY: 92ab5fb8e832105e-HKG [17] => alt-svc: h3=":443"; ma=86400 [18] => server-timing: cfL4;desc="?proto=TCP&rtt=45469&min_rtt=45369&rtt_var=12825&sent=5&recv=6&lost=0&retrans=0&sent_bytes=3001&recv_bytes=756&delivery_rate=63832&cwnd=33&unsent_bytes=0&cid=76adabc36f492c06&ts=227&x=0" ) 789

在中国武汉爆发新冠肺炎疫情持续延烧，周二由美国药厂吉利德科学公司研发的实验药品“瑞德西韦（Remdesivir）”有望成为抑制新冠肺炎的药物，却爆出被中国抢先注册专利的消息。更有甚者，中国药厂“博瑞生物医药”于周三公布，它们已成功仿制出该药品的“原料药合成工艺技术和制剂技术”，目前正在量产瑞德西韦制剂。